Data from mouse models for mild coronavirus infections and human tissue samples offer further evidence that it doesn’t take a severe infection—or even infection of brain cells at all—to cause long-term neurological symptoms.
Flu researchers propose H7N9 studies; NIH makes deal to share HeLa genome; herbal “remedies” can cause cancer; scientists record grid cell activity in humans
If approved, Proposition 14 would authorize the state to sell $5.5 billion in bonds to extend the life of CIRM, which funds stem cell research. The ballot measure has its critics.
At $2 million for a single dose, Novartis’s Zolgensma is the most expensive medicine to date, but still less expensive over a lifetime than another approved drug for the rare genetic disease.
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.